Comment 27 June
Sunday, June 27th, 2010It is not unusual for drugs to fail Phase 3 pivotal studies after showing success in Phase 2 studies. In fact, it is the norm rather than the exception. And this reality is not limited to experimental drugs … almost every major anti-cancer drug on the market today has failed at least one pivotal study [...]